Publications
Breast Cancer IndexSM Publications
Pivotal Clinical Studies- Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
- Breast Cancer Index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker
- Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
- HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease
- Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy
- Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
- Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial
- A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
- The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer
- A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
CancerTYPE ID® Publications and Scientific Presentations
Pivotal Clinical Studies- Blinded Comparator Study of Immunohistochemical Analysis versus a 92-Gene Cancer Classifier in the Diagnosis of the Primary Site in Metastatic Tumors
- Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
- Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier
- Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples
- A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors
- Physician-reported clinical utility of the 92-gene molecular classifier in tumors with uncertain diagnosis following standard clinicopathologic evaluation
- Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification
- A Retrospective Study of Treatment Outcomes in Patients with Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile
- Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction
- Molecular Classification of Human Cancers Using a 92-Gene Real-Time Quantitative Polymerase Chain Reaction Assay